Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach

CR Flowers, RW Anantha, V Leautaud… - Blood Cancer …, 2025 - aacrjournals.org
Hematologic malignancies exhibit disparities in risk and outcomes across populations. A
systematic review to identify prospective studies addressing disparities among patients with …

A simplified risk model for pretreatment stratification of newly diagnosed acute myeloid leukemia patients treated with venetoclax and azacitidine

N Islam, JS Reuben, JL Dale, J Zhang, JW Coates… - medRxiv, 2024 - medrxiv.org
Venetoclax plus azacitidine (ven/aza) is a new standard of care for adult Acute Myeloid
Leukemia (AML) patients who are not candidates for intensive therapies. Risk stratification …

Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis

M Drucker, D Lee, X Zhang, B Kain, M Bowman… - bioRxiv, 2024 - biorxiv.org
Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with
unique but related genotypes as initiating clones acquire subsequent mutations. However …

Leukemia-mutated proteins PHF6 and PHIP form a chromatin complex that represses myeloid leukemia stemness

AS Pawar, P Somers, A Alex, SS George, C Antony… - bioRxiv, 2024 - biorxiv.org
Myeloid leukemias are heterogeneous cancers with a diverse mutational landscape.
Though many mutated genes fall within common protein complexes, some lack known …

Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction value

Y Song, Z Wang, G Zhang, J Hou, K Liu, S Wei… - Molecular … - Wiley Online Library
Acute myeloid leukemia (AML) is a heterogeneous cancer, making outcomes prediction
challenging. Several predictive and prognostic models are used but have considerable …